INTRODUCTIONBreech presentation is the most common malpresentation. The incidence of breech presentation at term is 3-4%. Management of breech presentation at term is always being a topic of controversy. Day by day ECV is becoming a loosing Art. As delivery by Elective LSCS for Breech is associated with significantly lower neonatal mortality and morbidity, many obstetricians and pregnant women choose not to deliver breech babies vaginally. This is a significant contributing factor in increasing the caesarean rate and associated maternal morbidity.ECV has been definitely proven to decrease the incidence of breech at term.1 After rigorous scientific appraisal of several randomized controlled trials there has been renewed interest in external cephalic version in the last few years.2 American College of Obstetricians and Gynaecologists (2001) recommended that efforts should be made to reduce breech presentation by external cephalic version. 3 ABSTRACTBackground: Breech presentation is the most common malpresentation. The incidence of breech presentation at term is 3-4%. Objective of present study was to evaluate the outcome of external cephalic version (ECV) in singleton pregnancy with uncomplicated breech presentation at term in tertiary rural hospital and to analyze the immediate and ultimate outcome of external cephalic version done in term pregnancy with breech presentation with gestational age ≥37 weeks. Methods: This study was conducted at MIMER Medical college and BSTR Hospital, Talegaon Dabhade. Patients with breech presentation at term were studied over duration of 2½ years. 50 patients with breech presentation ≥37 weeks fulfilling the inclusion criteria underwent External cephalic version (ECV). Further obstetric progress is studied with the perinatal outcome and results were analyzed. Results: ECV was successful in 66% cases, out of which 88% cases had vaginal delivery and 12 % cases had LSCS for obstetric indication. Perinatal outcome was not affected with ECV. Conclusions: ECV at term significantly reduces both the incidence of breech delivery and caesarean section rate for breech delivery. ECV does not adversely affect the maternal and perinatal outcome.
Background: Ovarian masses are a frequent clinical diagnosis in general Gynecology. The aim of the present study was to assess risk factors, clinical features, CA 125 levels, histopathological diagnosis of the patients of all ovarian tumors that underwent surgical management between August 2013 to August 2017.Methods: This was the retrospective study conducted in the department of Obstetrics and Gynecology in MIMER Medical College. We studied 50 patients those who underwent surgical management. Most of the patients 56% were in the reproductive age group, 28% patients were in the perimenopausal age group, 14% were in the postmenopausal age group. 82% patients were parous.Results: Pain abdomen was most common symptom in 50% patients. Bilaterality of the tumor was common in malignant tumors. CA 125 was found to be increased more in malignant tumors. Most common co morbid condition was hypertension found in 12% patients. Most common ovarian tumor found was serous cystadenoma 34% and most common malignant tumors were serous cystadenoma carcinoma 16%.Conclusions: Out of all operated patients 11 (22%) were malignant, 37 (74%) were benign and 2 (%) were borderline tumors. Out of all malignant tumors 8 (72%) were serous cysadenocarcinoma. It is difficult to always differentiate between malignant and benign tumors clinically. Analysis of risk factors and protective factors, thorough abdomino-pelvicbimanual examination, certain features on radiological imaging, presence of ascites and bilaterality, CA125 levels, helps increasing the accuracy of the diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.